Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 9/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808030 | 1.00 | MMP13 (0.43) | MMP13NAMPTMMP1GAAPRKDC | |
| SCHEMBL12527286 | 1.00 | MMP13 (0.43) | MMP13NAMPTMMP1GAAPRKDC | |
| SCHEMBL29970973 | 0.90 | NAMPT (0.43) | MMP13NAMPTMMP1GAA | |
| SCHEMBL5319901 | 0.89 | MMP13 (0.45) | MMP13MMP1GAA | |
| SCHEMBL12705613 | 0.85 | GAA (0.46) | MMP13MMP1GAA | |
| SCHEMBL10276987 | 0.83 | NAMPT (0.41) | NAMPTPRKDCATMATR | |
| SCHEMBL29191944 | 0.83 | NAMPT (0.41) | NAMPTPRKDCATMATR | |
| SCHEMBL27651155 | 0.82 | PRKDC (0.46) | NAMPTPRKDCATMATR | |
| SCHEMBL13450398 | 0.82 | MCOLN3 (0.43) | NAMPTPRKDCATMATR | |
| SCHEMBL5761130 | 0.79 | GAA (0.52) | MMP13MMP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115244055-B | Pyrimidine five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-110305118-B | Synthetic method suitable for industrial production of enggliflozin | 四川科伦药物研究院有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4223751-A1 | BENZAMIDE COMPOUND AND USE THEREOF | Humanwell Healthcare (Group) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | HUMANWELL HEALTHCARE (GROUP) CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| CN-115244055-A | Pyrimido five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-110305118-A | A kind of synthetic method that suitable industrial production En Gelie is net | 四川科伦药物研究院有限公司 | 2019-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227445-A1 | BENZAMIDE COMPOUND AND USE THEREOF | P2RX3, P2RX4, P2RX7 | MMP13 3241/4885NAMPT 690/4885MMP1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.